CN114177356A - Preparation method and application of printing ink for photocuring 3D printing - Google Patents
Preparation method and application of printing ink for photocuring 3D printing Download PDFInfo
- Publication number
- CN114177356A CN114177356A CN202111514204.3A CN202111514204A CN114177356A CN 114177356 A CN114177356 A CN 114177356A CN 202111514204 A CN202111514204 A CN 202111514204A CN 114177356 A CN114177356 A CN 114177356A
- Authority
- CN
- China
- Prior art keywords
- hydrogel
- stirring
- printing
- printing ink
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000010146 3D printing Methods 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 238000000016 photochemical curing Methods 0.000 title claims abstract description 12
- 238000007639 printing Methods 0.000 title claims description 21
- 239000000017 hydrogel Substances 0.000 claims abstract description 77
- 238000003756 stirring Methods 0.000 claims abstract description 22
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 15
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229910021389 graphene Inorganic materials 0.000 claims abstract description 12
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 12
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000004113 cell culture Methods 0.000 claims abstract description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 5
- 125000004386 diacrylate group Chemical group 0.000 claims abstract description 5
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 238000013271 transdermal drug delivery Methods 0.000 claims abstract description 5
- 238000009210 therapy by ultrasound Methods 0.000 claims abstract description 4
- 229910021642 ultra pure water Inorganic materials 0.000 claims abstract description 4
- 239000012498 ultrapure water Substances 0.000 claims abstract description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 53
- 229940079593 drug Drugs 0.000 claims description 40
- 238000011068 loading method Methods 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000012286 potassium permanganate Substances 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 239000011240 wet gel Substances 0.000 claims description 6
- 230000002087 whitening effect Effects 0.000 claims description 6
- 239000011726 vitamin B6 Substances 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 4
- 206010000496 acne Diseases 0.000 claims description 4
- 230000003712 anti-aging effect Effects 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 claims description 4
- 239000008213 purified water Substances 0.000 claims description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 238000001308 synthesis method Methods 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 239000005457 ice water Substances 0.000 claims description 3
- 238000003760 magnetic stirring Methods 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000002407 tissue scaffold Substances 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 claims description 2
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims description 2
- RJZNPROJTJSYLC-LLINQDLYSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O RJZNPROJTJSYLC-LLINQDLYSA-N 0.000 claims description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- XDBMTQVSHNQIFU-UHFFFAOYSA-N 2-(2-ethoxy-2-oxo-1-phenylethyl)-1,3-thiazolidin-3-ium-4-carboxylate Chemical compound C=1C=CC=CC=1C(C(=O)OCC)C1NC(C(O)=O)CS1 XDBMTQVSHNQIFU-UHFFFAOYSA-N 0.000 claims description 2
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 2
- 108010024636 Glutathione Proteins 0.000 claims description 2
- 241000608867 Leucogenes Species 0.000 claims description 2
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Natural products OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 2
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229960000271 arbutin Drugs 0.000 claims description 2
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 claims description 2
- 229940022757 asiaticoside Drugs 0.000 claims description 2
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 claims description 2
- 235000013793 astaxanthin Nutrition 0.000 claims description 2
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 2
- 229940022405 astaxanthin Drugs 0.000 claims description 2
- 239000001168 astaxanthin Substances 0.000 claims description 2
- 229940036350 bisabolol Drugs 0.000 claims description 2
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 claims description 2
- 229960003276 erythromycin Drugs 0.000 claims description 2
- VRSMJNVXOITYPE-FSDIUQKZSA-N ethyl 4-[[(2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoyl]amino]benzoate Chemical group C1=CC(C(=O)OCC)=CC=C1NC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VRSMJNVXOITYPE-FSDIUQKZSA-N 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003180 glutathione Drugs 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 claims description 2
- 229960004705 kojic acid Drugs 0.000 claims description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 claims description 2
- 230000000388 leucogen effect Effects 0.000 claims description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 2
- 229960000282 metronidazole Drugs 0.000 claims description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 2
- 229960003471 retinol Drugs 0.000 claims description 2
- 235000020944 retinol Nutrition 0.000 claims description 2
- 239000011607 retinol Substances 0.000 claims description 2
- 125000002523 retinol group Chemical group 0.000 claims description 2
- 229960004889 salicylic acid Drugs 0.000 claims description 2
- 238000007910 systemic administration Methods 0.000 claims description 2
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims description 2
- 229960000401 tranexamic acid Drugs 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims 3
- IGAAQDGISNXKQL-UHFFFAOYSA-L P(=O)(OC(C1=C(C(=C(C=C1C)C)C1=CC=CC=C1)C)=O)([O-])[O-].[Li+].[Li+] Chemical group P(=O)(OC(C1=C(C(=C(C=C1C)C)C1=CC=CC=C1)C)=O)([O-])[O-].[Li+].[Li+] IGAAQDGISNXKQL-UHFFFAOYSA-L 0.000 claims 1
- 230000001153 anti-wrinkle effect Effects 0.000 claims 1
- 210000004413 cardiac myocyte Anatomy 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 210000003061 neural cell Anatomy 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 230000037317 transdermal delivery Effects 0.000 claims 1
- 239000000976 ink Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 14
- 239000000463 material Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 238000002386 leaching Methods 0.000 description 5
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 3
- 239000003431 cross linking reagent Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 206010034972 Photosensitivity reaction Diseases 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000010382 chemical cross-linking Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000001723 curing Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 230000036211 photosensitivity Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical compound C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- KLGDRWGOXDJNPH-UHFFFAOYSA-N P(=O)(O)(O)O.C1(=CC=CC=C1)C=1C(=C(C(=O)[Li])C(=CC1C)C)C Chemical compound P(=O)(O)(O)O.C1(=CC=CC=C1)C=1C(=C(C(=O)[Li])C(=CC1C)C)C KLGDRWGOXDJNPH-UHFFFAOYSA-N 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/24—Phosphorous; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8158—Homopolymers or copolymers of amides or imides, e.g. (meth) acrylamide; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y10/00—Processes of additive manufacturing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y70/00—Materials specially adapted for additive manufacturing
- B33Y70/10—Composites of different types of material, e.g. mixtures of ceramics and polymers or mixtures of metals and biomaterials
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y80/00—Products made by additive manufacturing
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F2/00—Processes of polymerisation
- C08F2/46—Polymerisation initiated by wave energy or particle radiation
- C08F2/48—Polymerisation initiated by wave energy or particle radiation by ultraviolet or visible light
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F283/00—Macromolecular compounds obtained by polymerising monomers on to polymers provided for in subclass C08G
- C08F283/06—Macromolecular compounds obtained by polymerising monomers on to polymers provided for in subclass C08G on to polyethers, polyoxymethylenes or polyacetals
- C08F283/065—Macromolecular compounds obtained by polymerising monomers on to polymers provided for in subclass C08G on to polyethers, polyoxymethylenes or polyacetals on to unsaturated polyethers, polyoxymethylenes or polyacetals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2535/00—Supports or coatings for cell culture characterised by topography
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2537/00—Supports and/or coatings for cell culture characterised by physical or chemical treatment
- C12N2537/10—Cross-linking
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention relates to 3D printing, in particular to a preparation method and application of photocuring 3D printing ink; a preparation method of photocuring 3D printing ink is characterized by comprising the following steps: adding 50-100 mg of graphene oxide powder into 100mL of ultrapure water, and carrying out ultrasonic treatment for 1-3 h until the graphene oxide is uniformly dispersed; adding 15-20 g of acrylamide and 1-5 g of polyethylene glycol (glycol) diacrylate, adding a photoinitiator, stirring and dissolving to obtain the 3D printing ink. The 3D printing ink prepared by the invention has excellent biocompatibility and mechanical property, provides possibility for personalized customization of hydrogel, and has great application space in the fields of transdermal drug delivery, skin cosmetology, cell culture, tissue engineering and the like.
Description
Technical Field
The invention relates to the field of 3D printing, and relates to a preparation method and application of printing ink for photocuring 3D printing.
Background
The traditional hydrogel is usually prepared by a die method, the method has poor design flexibility, only can prepare hydrogels with certain basic shapes depending on die shaping, sometimes the hydrogels with different sizes and different shapes can be prepared according to actual requirements, and the prepared hydrogels need to be secondarily processed or correspondingly use dies with specific sizes and shapes. The 3D printing one-step forming has the advantages that the problems that a mold is needed and the process is complicated in the traditional hydrogel preparation method are expected to be solved, and based on the characteristic that the 3D model is flexible and controllable in design, the hydrogel shape with a more complex and finer structure can be prepared, particularly the photocuring 3D printing technology with the most potential in the 3D printing technology is high in precision and speed, and the hydrogel has great potential in the aspect of personalized customization. However, the technology has certain limitations, the molding conditions are harsh, the materials are required to have photosensitivity, most of the materials have high toxicity and few available materials, the materials commonly used in the field of medicine at present mainly comprise GelMA, HAMA, PEGDA and the like, and the materials have photosensitivity and excellent biocompatibility but have the problems of poor mechanical strength and the like.
Aiming at the problems, the printing ink for photocuring 3D printing is developed, the hydrogel prepared by printing has excellent biocompatibility and mechanical properties, the possibility is provided for personalized customization of the hydrogel, and the printing ink has a large application space in the fields of transdermal drug delivery, skin cosmetology, cell culture, tissue engineering and the like.
Disclosure of Invention
Object of the Invention
The invention mainly provides a preparation method and application of printing ink for photocuring 3D printing.
Technical scheme
A preparation method of photocuring 3D printing ink is characterized by comprising the following steps: adding 50-100 mg of graphene oxide powder into 100mL of ultrapure water, and carrying out ultrasonic treatment for 1-3 h until the graphene oxide is uniformly dispersed; adding 15-20 g of acrylamide and 1-5 g of polyethylene glycol (glycol) diacrylate, adding a photoinitiator, stirring and dissolving to obtain the 3D printing ink.
The synthesis method of the Graphene Oxide (GO) comprises the following steps: weighing 50mL of concentrated sulfuric acid, putting the concentrated sulfuric acid into a beaker, adding 2g of 400-mesh graphite powder and 1g of NaNO3, and stirring in an ice-water bath for 30 min; slowly adding 3g KMnO4, stirring for 30min, and controlling temperature below 10 deg.C; adding 7g of KMnO4 into a beaker in 3 batches, and continuing to react for 1h, wherein the temperature is controlled below 20 ℃; raising the temperature to 35 ℃, and fully stirring for 2 hours to obtain a brown suspension; slowly adding 60mL of water, stirring for 15min, continuously reacting for 30min, cooling to 50 ℃, adding an H2O2 aqueous solution until no bubbles are generated, and changing the system from black to bright yellow; centrifuging at 9000rpm for 5min, washing the precipitate with 5% hydrochloric acid for 3 times, washing with purified water for 4 times to obtain yellow brown graphene oxide solution, and freeze drying for 48 h.
The synthesis method of the polyethylene glycol (glycol) diacrylate (PEGDA) comprises the following steps: putting PEG with the number average molecular weight of 400 in a beaker, measuring anhydrous dichloromethane, adding the anhydrous dichloromethane into the beaker, stirring until the PEG is completely dissolved, then adding 0.7mL of triethylamine and 1.5mL of acryloyl chloride under the condition of magnetic stirring at 45 ℃, continuously stirring for reaction for 48h under the protection of N2, and purifying to obtain the PEGDA.
A preparation method of a 3D printing hydrogel patch is characterized by comprising the following steps: and printing the drawn 3D printing model by using the photocuring 3D printer according to the drawn 3D printing ink.
The hydrogel prepared by the method is loaded with drugs, and is characterized in that: the drug loading can be carried out by two methods, namely a xerogel drug loading method and a wet gel drug loading method, and the hydrogel after drug loading has a certain controlled release effect.
The hydrogel prepared by the method is used for cell culture and tissue scaffold construction, and is characterized in that: drawing a tissue scaffold model according to the requirement, printing by a 3D printer to obtain a hydrogel scaffold, and adding cells to enable the hydrogel scaffold to grow on the surface.
The application of the hydrogel in the field of transdermal drug delivery includes but is not limited to: A. a dressing for wounds, characterized in that: a model is drawn through 3D modeling software, the printing ink is used for printing, and the obtained hydrogel patch can be used as a wound auxiliary material and has the advantages of absorbing exudate, being reusable and being customized in a personalized mode. B. For drug loading, characterized by: the model is drawn through 3D modeling software, the printing ink is used for printing to obtain a blank hydrogel patch, drug loading can be carried out through two modes, namely a xerogel drug loading method and a wet gel drug loading method, and the hydrogel after drug loading has a certain controlled release effect.
The application of the hydrogel in the field of cosmetology and pharmacy is characterized in that: drawing model with 3D modeling software, printing with the above printing ink, and adding active ingredients such as vitamin C and vitamin B6The gel is loaded by the xerogel drug loading method or the wet gel drug loading method, and has the effects of whitening, removing freckles, repairing and the like.
The application is characterized in that: the medicine is antibacterial medicine, acne treating medicine, whitening substance, skin repairing substance or anti-aging substance.
The application is characterized in that: the antibacterial agent is erythromycin and metronidazole; the medicine for treating acne is viaminate, salicylic acid; drugs for systemic administration; the whitening substance is vitamin C and its derivatives, vitamin E, nicotinamide, arbutin, glutathione, tranexamic acid, astaxanthin, and kojic acid; the skin repairing substance is vitamin B6Ceramide, bisabolol, asiaticoside, growth factor; the anti-aging substance is retinol and its derivatives, leucogen, palmitoyl tripeptide, and acetyl hexapeptide.
The innovation points are as follows:
according to the invention, a traditional polyacrylamide gel crosslinking system is improved, graphene oxide is introduced to enhance the mechanical property of the formed hydrogel and increase the antibacterial property of the formed hydrogel, PEGDA replaces the traditional crosslinking agent N, N' -methylene bisacrylamide (Bis), so that the formed hydrogel has excellent flexibility and tensile property, the breaking elongation of the formed hydrogel can reach 1024.15%, Table 1 compares the mechanical property parameters of acrylamide hydrogels with three different components, and the hydrogel obtained by using the crosslinking agent Bis has higher rigidity but poorer tensile property; the use of PEGDA as a cross-linker significantly enhances the stretchability of the shaped hydrogel, but sacrifices the rigidity of the system. The addition of GO increases the rigidity of the system and simultaneously retains the tensile property brought by PEGDA, because the graphene oxide surface has rich oxygen-containing hydrophilic functional groups such as-COOH, -OH, epoxy bonds and the like, and the rigidity of the hydrogel is increased by forming hydrogen bonds with polyacrylamide chains. The traditional chemical crosslinking is replaced by a photocrosslinking method, and the obtained 3D printing ink has great application prospects in the fields of transdermal drug delivery, cell culture and tissue engineering.
TABLE 1 mechanical Properties of different acrylamide hydrogels
Description of the drawings:
FIG. 1 is a range analysis graph of the results of the orthogonal test;
fig. 2 in vitro release curves of drug-loaded 3D printed hydrogels (a) xerogel drug loading method (b) wet gel drug loading method;
fig. 33D is a printed hydrogel patch, where (a) is the hydrogel immediately after printing and not yet detached from the printing platform (b) is the hydrogel detached from the platform (c) is a porous structure clearly visible on the hydrogel surface;
figure 43D illustrates the adhesion and flexibility of a printed hydrogel patch, wherein (a) the adhesion of the hydrogel patch to a smooth stainless steel plane (b) is a graph demonstrating the excellent stretchability of the hydrogel;
FIG. 5 SEM image (100 μm) of hydrogel.
Detailed Description
LAP (photoinitiator), fully known as phenyl (2,4, 6-trimethylbenzoyl) lithium phosphate, was purchased from Shanghai Leichang Innovative materials, Inc.
Example 1
(1) Synthesizing graphene oxide:
50mL of concentrated sulfuric acid is measured and put into a beaker, 2g of 400-mesh graphite powder and 1g of NaNO are added3Stirring in ice water bath for 30 min; slowly add 3g KMnO4Stirring thoroughly for 30min, and controlling the temperature below 10 deg.C; 7g of KMnO4Adding the mixture into beakers in 3 batches, and continuously reacting for 1 hour, wherein the temperature is controlled below 20 ℃; raising the temperature to 35 ℃, and fully stirring for 2 hours to obtain a brown suspension; slowly adding 60mL of water, stirring for 15min, suddenly increasing the temperature of the system to 90 ℃ with generation of a large amount of gas,continuing to react for 30min, cooling to 50 ℃, and adding H2O2When the water solution does not generate bubbles, the system is changed from black to bright yellow, which indicates that the graphene oxide is successfully prepared; centrifuging at 9000rpm for 5min, washing the precipitate with 5% hydrochloric acid for 3 times, washing with purified water for 4 times to obtain yellow brown graphene oxide solution, and freeze drying for 48 h.
(2) Synthesis of PEGDA:
PEG (Mn 400) was weighed and placed in a beaker, and anhydrous dichloromethane (CaCl) was measured2Water removal, PEG: CH (CH)2Cl21:5), stirring until the PEG is completely dissolved, adding 0.7mL of triethylamine and 1.5mL of acryloyl chloride under magnetic stirring at 45 ℃, and adding N2The reaction was kept stirring for 48h under protective conditions. After the reaction is finished, adding 25mL (2mol/L) of potassium carbonate solution into the reaction solution to remove a reaction by-product HCl, transferring the solution to a separating funnel, fully oscillating, standing for 5 hours, separating, taking a lower-layer dichloromethane solution, adding magnesium sulfate powder, and drying; centrifuging to obtain supernatant, rotary-steaming to obtain concentrated solution, adding diethyl ether until white powder sample is separated out, vacuum filtering to remove diethyl ether, collecting the sample, drying in a vacuum drier for 24h, sealing, and storing in dark place.
(3) Preparation of 3D printing ink:
adding 50-100 mg (0.05% -0.1%) of GO powder into 100mL of ultrapure water, and carrying out ultrasonic treatment for 2h until the GO is uniformly dispersed; adding 15-20 g (15-20%) of acrylamide, 1-5 g (0.1-0.5%) of PEGDA and 25-100 mg of LAP, stirring and dissolving to obtain the 3D printing ink.
EXAMPLE 23 formulation screening of printing inks
Selecting three important influence factors of acrylamide concentration (A), GO concentration (B) and PEGDA concentration (C), wherein the factor levels are shown in table 2, the elongation at break and sensory score of the hydrogel are used as evaluation indexes, the comprehensive score is 0.2% multiplied by elongation at break + 0.8% multiplied by sensory score, and the three factors are used for three levels (L)9，33) The results of the orthogonal design and the orthogonal test are shown in table 3. The results of the cross test are subjected to range analysis, the results are shown in figure 1, and the influence on the comprehensive performance of the hydrogel A can be seen from the figure>C>B, as can be seen from the figure, so as to synthesizeThe largest scoring prescription is A3B2C1, namely 20% acrylamide, 0.05% GO and 0.2% PEGDA, wherein the hydrogel using 1% PEGDA loses elasticity, the 10% hydrogel is not suitable for 3D printing due to low crosslinking degree, the acrylamide concentration is 15% -20%, and the PEGDA concentration is 0.1% -0.5%, so that good hydrogel performance can be obtained.
TABLE 2 factor level table
TABLE 3 results of orthogonal experiments
Example 3
In this example, the drug loading was carried out by the following method and the in vitro drug release performance of the drug-loaded hydrogel was investigated, and the model drug used was vitamin B6The method comprises the following specific implementation steps:
(1) vitamin B-carrying6Preparation of hydrogel:
xerogel drug loading method: cutting the hydrogel patch prepared by 3D printing into small blocks of 10 multiplied by 2mm, freeze-drying for 24h to obtain freeze-dried hydrogel, immersing the hydrogel into medicine liquid containing 5mg of medicine, and completely sucking the medicine liquid by utilizing the swelling property to obtain the medicine-carrying hydrogel.
Wet gel drug loading method: immersing the aqueous hydrogel in a solution containing 5mg of vitamin B6The concentrated liquid medicine of (2) is loaded by utilizing the diffusion effect of the drug.
(2) In vitro drug release experiment:
the drug-loaded hydrogel is soaked in 50mL of release medium, placed in a constant temperature shaking table at 37 ℃, and 1mL of release medium is taken out while 1mL of new release medium is supplemented for 2,4,6, 8, 10, 12 and 24 hours to keep the total volume of the solution unchanged. The value of the release taken out and the absorbance value measured at 290nm are used for calculating the concentration and the cumulative release rate according to the standard curve. Figure 2 is an in vitro drug release profile of a drug loaded hydrogel. Under two different drug loading modes, about 50% of the drug is released into the medium when the drug is quickly released in the first 2 hours, the release of the drug gradually becomes slow after 2 hours, the drug starts to enter a plateau period about 8 hours, the drug is completely released in 10 hours, and the cumulative release rate is about 85%, so that the hydrogel has good drug loading capacity and a certain controlled release effect.
Example 4
This example performs a hydrogel biocompatibility experiment by the following method:
preparing a hydrogel leaching solution:
placing acrylamide hydrogel into DEME complete culture medium (0.3g/mL) containing 10% fetal bovine serum, placing in a constant temperature shaking table at 37 deg.C for 24h, and taking out the leaching solution. Filtering the leaching solution with 0.22 μ L sterile microporous membrane, and storing at low temperature.
MTT method for detecting cytotoxicity:
taking cells in logarithmic growth phase, digesting with pancreatin to obtain cell suspension, counting cells, and regulating cell concentration to 5 × 104The cell suspension was seeded in a 96-well plate at 200. mu.L per well, and 6 wells were set. Standing at 37 deg.C for 5% CO2Culturing in a cell culture box overnight, discarding culture solution, replacing the experimental group with acrylamide hydrogel leaching liquor, replacing the control group and the blank group with fresh complete culture medium, and setting 6 multiple holes in each group. Placing the 96-well plate after liquid replacement at 37 ℃ with the volume fraction of 5% CO2The culture is continued in the constant temperature incubator for 1, 2 and 3 days, and then the culture is taken out for MTT experiment. The supernatant was discarded, 200. mu.l of MTT solution (0.5mg/ml) was added to each well, and the mixture was incubated at 37 ℃ with 5% CO by volume2The incubator of (1) was incubated for 4 hours. After 4h, the plate was discarded and 200. mu.L of dimethyl sulfoxide was added to each well and shaken on a shaker for 15 min. The absorbance value (A) at 490nm was measured for each well using a microplate reader. The Relative Growth Rate (RGR) of the cells was calculated according to the following equation.
RGR (%) ═ (experimental a-placebo a)/(control a-placebo a) × 100%.
After the hydrogel leaching liquor is co-cultured with cells for 1, 2, 3 and 4 days, the cell proliferation rates are respectively 91.8%, 95.4% and 93.8% and 89.1%, which indicates that the hydrogel has good biocompatibility.
Example 5
This example personalizes a custom hydrogel for use as a wound dressing by the following method:
drawing a model through solid work three-dimensional modeling software, setting printer parameters to be 30 micrometers of the thickness of a single-layer printing layer, 15 seconds of single-layer curing time, 30 seconds of base layer curing time and 5 layers of base layer, and introducing 3D printing ink into an ink tank to start printing. FIG. 3 is a printed hydrogel patch with the hydrogel surface structure clearly visible, consistent with the designed model; fig. 4 shows the adhesiveness and flexibility of the hydrogel patch, the 3D-printed patch has excellent flexibility, can be stretched repeatedly, and the shape is not damaged, and meanwhile, the hydrogel patch has certain adhesion performance, and is attached to the surface of a smooth stainless steel plate and applied with certain pressure, and the hydrogel is well adhered to the surface and cannot fall off spontaneously; fig. 5 is an SEM electron micrograph of the hydrogel, and it can be seen from the micrograph that the hydrogel has a porous structure inside to provide a small molecule access channel for the hydrogel, which can realize the access of moisture and the exchange of other small molecule substances, and can absorb exudate as a wound dressing.
Comparative example 1
The traditional acrylamide hydrogel takes acrylamide as a monomer, N, N' -methylene bisacrylamide as a cross-linking agent and potassium persulfate and sodium bisulfite as initiators, and the specific preparation method comprises the following steps: acrylamide is dissolved in purified water, an initiator (potassium persulfate: sodium bisulfite ═ 1:1) and N, N' -methylene bisacrylamide are sequentially added, the mixture is stirred for 1 hour at the temperature of 80 ℃, and the mixture is poured into a mold to be cooled to obtain hydrogel. The method is chemical crosslinking, has long preparation time and depends on mold shaping, and the hydrogel prepared by the method has crisp texture and poor mechanical property.
The present invention is not limited to the above-described embodiments, and any obvious improvements, substitutions or modifications can be made by those skilled in the art without departing from the spirit of the present invention.
Claims (10)
1. A preparation method of photocuring 3D printing ink is characterized by comprising the following steps: adding 50-100 mg of graphene oxide powder into 100mL of ultrapure water, and carrying out ultrasonic treatment for 1-3 h until the graphene oxide is uniformly dispersed; adding 15-20 g of acrylamide and 1-5 g of polyethylene glycol (glycol) diacrylate, adding a photoinitiator, stirring and dissolving to obtain the 3D printing ink.
2. The method according to claim 1, wherein the photoinitiator is lithium phenyl (2,4, 6-trimethylbenzoyl) phosphate.
3. A method of preparing a 3D printing ink according to claim 1, characterized in that:
the synthesis method of the Graphene Oxide (GO) comprises the following steps: 50mL of concentrated sulfuric acid is measured and put into a beaker, 2g of 400-mesh graphite powder and 1g of NaNO are added3Stirring in ice water bath for 30 min; slowly add 3g KMnO4Stirring thoroughly for 30min, and controlling the temperature below 10 deg.C; 7g of KMnO4Adding the mixture into beakers in 3 batches, and continuously reacting for 1 hour, wherein the temperature is controlled below 20 ℃; raising the temperature to 35 ℃, and fully stirring for 2 hours to obtain a brown suspension; slowly adding 60mL of water, stirring for 15min, continuously reacting for 30min, cooling to 50 ℃, adding H2O2The water solution does not generate bubbles, and the system changes from black to bright yellow; centrifuging at 9000rpm for 5min, washing the precipitate with 5% hydrochloric acid for 3 times, washing with purified water for 4 times to obtain yellow brown graphene oxide solution, and freeze drying for 48 hr;
the synthesis method of the polyethylene glycol (glycol) diacrylate (PEGDA) comprises the following steps: putting PEG with number average molecular weight of 400 in a beaker, measuring anhydrous dichloromethane, adding into the beaker, stirring until the PEG is completely dissolved, sequentially adding 0.7mL triethylamine and 1.5mL acryloyl chloride under the condition of magnetic stirring at 45 ℃, and adding N2Continuously stirring and reacting for 48h under the protection condition, and purifying to obtain the PEGDA.
4. A preparation method of a 3D printing hydrogel patch is characterized by comprising the following steps: printing ink according to any one of claims 1 to 3, printed using a photocuring 3D printer in accordance with the rendered 3D printing model.
5. Use of a hydrogel patch prepared by the method of claim 4 for the preparation of a drug loaded carrier, wherein: the hydrogel can be loaded with drugs by a xerogel drug loading method or a wet gel drug loading method.
6. Use of the hydrogel patch prepared by the method of claim 4 as a cell culture or tissue scaffold, characterized in that: adding cells to grow, induce and differentiate on the surface of the scaffold to form tissues; wherein the cells capable of being cultured comprise Hacat cells, cardiomyocytes or neural cells; the tissue may comprise myocardial tissue, neural tissue or skin.
7. Use according to claim 5, wherein the hydrogel patch is for use in a transdermal drug delivery system.
8. The use according to claim 7, wherein the transdermal delivery system is for the delivery of substances or drugs having whitening, anti-wrinkle, healing, or reparative functions.
9. Use according to claim 8, characterized in that: the medicine is antibacterial medicine, acne treating medicine, whitening substance, skin repairing substance or anti-aging substance.
10. Use according to claim 8, characterized in that: the antibacterial agent is erythromycin and metronidazole; the medicine for treating acne is viaminate, salicylic acid; drugs for systemic administration; the whitening substance is vitamin C and its derivatives, vitamin E, nicotinamide, arbutin, glutathione, tranexamic acid, astaxanthin, and kojic acid; the skin repairing substance is vitamin B6Ceramide, bisabolol, asiaticoside, growth factor; the anti-aging substance is retinol and its derivatives, leucogen, palmitoyl tripeptide, and acetyl hexapeptide.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111514204.3A CN114177356B (en) | 2021-12-13 | 2021-12-13 | Preparation method and application of printing ink capable of being used for photo-curing 3D printing |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111514204.3A CN114177356B (en) | 2021-12-13 | 2021-12-13 | Preparation method and application of printing ink capable of being used for photo-curing 3D printing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114177356A true CN114177356A (en) | 2022-03-15 |
| CN114177356B CN114177356B (en) | 2023-05-09 |
Family
ID=80543354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111514204.3A Active CN114177356B (en) | 2021-12-13 | 2021-12-13 | Preparation method and application of printing ink capable of being used for photo-curing 3D printing |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114177356B (en) |
Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102229683A (en) * | 2010-12-13 | 2011-11-02 | 北京理工大学 | Preparation method of graphene based nano composite hydrogel |
| JP2012051993A (en) * | 2010-08-31 | 2012-03-15 | Kumamoto Univ | Method for producing graphene-polymer composite material and graphene-polymer composite material produced by using the same |
| US20130230496A1 (en) * | 2012-02-23 | 2013-09-05 | Subhra Mohapatra | Graphene hydrogel and method for using the same |
| CN103819656A (en) * | 2014-02-18 | 2014-05-28 | 青岛科技大学 | Graphene oxide/light cured resin composite and its preparation method and application |
| CN106317263A (en) * | 2016-08-23 | 2017-01-11 | 浙江理工大学 | Visible light initiating system in medical photo-curing hydrogel and photo-curing method thereof |
| CN106478962A (en) * | 2016-09-26 | 2017-03-08 | 东华大学 | A kind of preparation method of hyaluronic acid/graphene oxide/polyacrylamide composite aquogel |
| CN106893052A (en) * | 2017-03-13 | 2017-06-27 | 东北大学秦皇岛分校 | A kind of preparation method of graphene oxide/polyacrylamide composite aquogel |
| CN108084342A (en) * | 2017-11-27 | 2018-05-29 | 南京航空航天大学 | A kind of water soluble photo-curable 3D printing backing material and preparation method thereof |
| CN108164656A (en) * | 2018-01-29 | 2018-06-15 | 中国石油大学(华东) | A kind of hydrogel and its preparation method and application |
| CN109111555A (en) * | 2018-07-18 | 2019-01-01 | 海南师范大学 | A kind of preparation method of high-performance bio compatibility radical photopolymerization visible light initiation system |
| CN109851727A (en) * | 2019-01-04 | 2019-06-07 | 东南大学 | A kind of thixotropy photocuring hydrogel and its preparation method and application |
| US20210071018A1 (en) * | 2019-09-11 | 2021-03-11 | Board Of Regents, The University Of Texas System | Compositions and methods for extrusion-based 3d printing of soft materials |
| CN113292678A (en) * | 2021-06-08 | 2021-08-24 | 中国科学院兰州化学物理研究所 | Hydrogel ink and direct-writing 3D printing ionic conductive hydrogel |
| WO2021240150A1 (en) * | 2020-05-27 | 2021-12-02 | G2O Water Technologies Limited | Oil and water separation membrane |
-
2021
- 2021-12-13 CN CN202111514204.3A patent/CN114177356B/en active Active
Patent Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012051993A (en) * | 2010-08-31 | 2012-03-15 | Kumamoto Univ | Method for producing graphene-polymer composite material and graphene-polymer composite material produced by using the same |
| CN102229683A (en) * | 2010-12-13 | 2011-11-02 | 北京理工大学 | Preparation method of graphene based nano composite hydrogel |
| US20130230496A1 (en) * | 2012-02-23 | 2013-09-05 | Subhra Mohapatra | Graphene hydrogel and method for using the same |
| CN103819656A (en) * | 2014-02-18 | 2014-05-28 | 青岛科技大学 | Graphene oxide/light cured resin composite and its preparation method and application |
| CN106317263A (en) * | 2016-08-23 | 2017-01-11 | 浙江理工大学 | Visible light initiating system in medical photo-curing hydrogel and photo-curing method thereof |
| CN106478962A (en) * | 2016-09-26 | 2017-03-08 | 东华大学 | A kind of preparation method of hyaluronic acid/graphene oxide/polyacrylamide composite aquogel |
| CN106893052A (en) * | 2017-03-13 | 2017-06-27 | 东北大学秦皇岛分校 | A kind of preparation method of graphene oxide/polyacrylamide composite aquogel |
| CN108084342A (en) * | 2017-11-27 | 2018-05-29 | 南京航空航天大学 | A kind of water soluble photo-curable 3D printing backing material and preparation method thereof |
| CN108164656A (en) * | 2018-01-29 | 2018-06-15 | 中国石油大学(华东) | A kind of hydrogel and its preparation method and application |
| CN109111555A (en) * | 2018-07-18 | 2019-01-01 | 海南师范大学 | A kind of preparation method of high-performance bio compatibility radical photopolymerization visible light initiation system |
| CN109851727A (en) * | 2019-01-04 | 2019-06-07 | 东南大学 | A kind of thixotropy photocuring hydrogel and its preparation method and application |
| US20210071018A1 (en) * | 2019-09-11 | 2021-03-11 | Board Of Regents, The University Of Texas System | Compositions and methods for extrusion-based 3d printing of soft materials |
| WO2021240150A1 (en) * | 2020-05-27 | 2021-12-02 | G2O Water Technologies Limited | Oil and water separation membrane |
| CN113292678A (en) * | 2021-06-08 | 2021-08-24 | 中国科学院兰州化学物理研究所 | Hydrogel ink and direct-writing 3D printing ionic conductive hydrogel |
Non-Patent Citations (5)
| Title |
|---|
| YANG, LIAI等: "Construction of biocompatible bilayered light-driven actuator composed of rGO/PNIPAM and PEGDA hydrogel", 《JOURNAL OF APPLIED POLYMER SCIENCE》 * |
| 吴寒: "氧化石墨烯改性pNIPAAm水凝胶在细胞片层工程中的应用", 《中国优秀硕士学位论文全文数据库 基础科学辑》 * |
| 杨继全等著: "《异质材料3D打印技术》", 31 March 2019, 武汉：华中科技大学出版社 * |
| 王云云主编: "《药物制剂技术》", 31 August 2016, 重庆：重庆大学出版社 * |
| 董建军等编著: "《丙烯酸盐灌浆材料在水工建筑物中的应用》", 30 September 2019, 武汉：长江出版社 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114177356B (en) | 2023-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cho et al. | Recent progress in self-healing polymers and hydrogels based on reversible dynamic B–O bonds: boronic/boronate esters, borax, and benzoxaborole | |
| Marrella et al. | Enhanced mechanical performances and bioactivity of cell laden-graphene oxide/alginate hydrogels open new scenario for articular tissue engineering applications | |
| EP1970400B1 (en) | Stimuli-responsive degradable gel | |
| CN104744661A (en) | Hydrophilic degradable segmented polyurethane as well as preparation method and application thereof | |
| Zhou et al. | A super-stretchable, self-healing and injectable supramolecular hydrogel constructed by a host–guest crosslinker | |
| Qian et al. | Preparation and characterization of bimodal porous poly (γ-benzyl-L-glutamate) scaffolds for bone tissue engineering | |
| CN110181806B (en) | Low-temperature 3D printing method of biodegradable waterborne polyurethane with biocompatibility | |
| CN108815574A (en) | Bone repair hydrogel bracket and preparation method thereof | |
| WO2019123259A1 (en) | Hydrogels based on blood plasma components, process and uses thereof | |
| KR100794174B1 (en) | Preparation method of biodegradable porous polymer scaffolds containing hydroxyapatite for tissue engineering | |
| WO2019095610A1 (en) | Method for quick gelation of silk fibroin solution under physiological conditions | |
| CN115028903A (en) | Hydrogel and preparation method and application thereof | |
| CN108452375A (en) | A kind of graphene oxide conductive hydrogel of 3D printing and its preparation method and application | |
| CN114177356B (en) | Preparation method and application of printing ink capable of being used for photo-curing 3D printing | |
| CN109705359B (en) | Modified polyethylene glycol-polysebacic acid (PEGS) injectable biological elastomer and preparation method and application thereof | |
| Chen et al. | Functionalized gelatin/strontium hydrogel bearing endothelial progenitor cells for accelerating angiogenesis in wound tissue regeneration | |
| Cheng et al. | A self-healing hydrogel and injectable cryogel of gelatin methacryloyl-polyurethane double network for 3D printing | |
| CN114668745B (en) | Glucose and H 2 O 2 Double-response double-layer crosslinked polymer nano drug delivery system and preparation method and application thereof | |
| CN108084466B (en) | Composite membrane based on egg white and methacrylic acid derivative polymer and application of composite membrane in stem cell culture | |
| JP5935181B2 (en) | Biomaterial for wound healing and its preparation | |
| CN113858610B (en) | Medical fibrous surface dressing and preparation method and application thereof | |
| Qian et al. | Preparation and characterization of biomorphic poly (l-lactide-co-β-malic acid) scaffolds | |
| CN113956506A (en) | Double-network hydrogel and preparation method and application thereof | |
| CN107629437A (en) | The high intensity hydrogel and its application in 3D printing of a kind of pH and temperature double responsiveness | |
| KR101803179B1 (en) | A method for preparing a pH-sensitive 3D scaffold and a cell culture scaffold using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |